StreetInsider.com News Articles

TD Cowen Starts Sol Gel Technologies Ltd. (SLGL) at Buy

Fri, 29 May 2026 05:30:16 -0400

TD Cowen analyst Stacy Ku initiates coverage on Sol Gel Technologies Ltd. (NASDAQ: SLGL) with a Buy rating.

The analyst comments "We are initiating coverage of SLGL with a Buy rating. SGT-610 (topical hedgehog inhibitor/HHI patidegib 2%) is in a refined/optimized Phase III for treatment of BCCs in Gorlin syndrome, with data in Q4. KOLs highlight the large unmet need for alternatives to Moh surgeries, given patient fatigue. '610 is derisked by oral HHIs, with improved tolerability and low efficacy hurdle for a $550MM+ oppy."

For an analyst ratings summary and ratings history on Sol Gel Technologies Ltd. click here. For

TD Cowen Starts Sol Gel Technologies Ltd. (SLGL) at Buy

Fri, 29 May 2026 05:30:16 -0400

TD Cowen analyst Stacy Ku initiates coverage on Sol Gel Technologies Ltd. (NASDAQ: SLGL) with a Buy rating.

For an analyst ratings summary and ratings history on Sol Gel Technologies Ltd. click here. For

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 28 May 2026 08:00:00 -0400

Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044
Sol-Gel completed an oversubscribed underwritten offering, raising gross proceeds of approximately $33.1 million from leading healthcare specialist investors
Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in the fourth quarter of 2026
Sol-Gel signed an exclusive license agreement with Sun Pharmaceutical Industries Ltd. for the commercialization of TWYNEO® in India

NESS ZIONA, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology

Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates

Thu, 28 May 2026 08:00:00 -0400

Sol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044
Sol-Gel completed an oversubscribed underwritten offering, raising gross proceeds of approximately $33.1 million from leading healthcare specialist investors
Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in the fourth quarter of 2026
Sol-Gel signed an exclusive license agreement with Sun Pharmaceutical Industries Ltd. for the commercialization of TWYNEO® in India

NESS ZIONA, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology

Form 6-K Sol-Gel Technologies For: May 28

Thu, 28 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260528/26561459.html

Form 6-K Sol-Gel Technologies For: May 28

Thu, 28 May 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260528/26561459.html

Form 4 Sol-Gel Technologies For: May 20 Filed by: Opaleye Management Inc.

Fri, 22 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260522/26541521.html

Form 4 Sol-Gel Technologies For: May 20 Filed by: Opaleye Management Inc.

Fri, 22 May 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260522/26541521.html

Form 4 Sol-Gel Technologies For: May 12 Filed by: Opaleye Management Inc.

Thu, 14 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260514/26494622.html

Form 4 Sol-Gel Technologies For: May 12 Filed by: Opaleye Management Inc.

Thu, 14 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260514/26494622.html

Form SCHEDULE 13G/A Sol-Gel Technologies Filed by: Opaleye Management Inc.

Wed, 06 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260506/26443570.html

Form SCHEDULE 13G/A Sol-Gel Technologies Filed by: Opaleye Management Inc.

Wed, 06 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260506/26443570.html

Form SCHEDULE 13D/A Sol-Gel Technologies Filed by: Arkin Moshe

Wed, 15 Apr 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260415/26317366.html

Form SCHEDULE 13D/A Sol-Gel Technologies Filed by: Arkin Moshe

Wed, 15 Apr 2026 12:38:00 -0400

si-local-file:///var/storage/secattach/20260415/26317366.html

Form SCHEDULE 13G Sol-Gel Technologies Filed by: GREAT POINT PARTNERS LLC

Tue, 31 Mar 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260331/26252968.html

Form SCHEDULE 13G Sol-Gel Technologies Filed by: GREAT POINT PARTNERS LLC

Tue, 31 Mar 2026 18:03:00 -0400

si-local-file:///var/storage/secattach/20260331/26252968.html

Form 6-K Sol-Gel Technologies For: Mar 24

Tue, 24 Mar 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260324/26211515.html

Form 6-K Sol-Gel Technologies For: Mar 24

Tue, 24 Mar 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260324/26211515.html

Form 424B5 Sol-Gel Technologies

Tue, 24 Mar 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260324/26211496.html

Form 424B5 Sol-Gel Technologies

Tue, 24 Mar 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20260324/26211496.html

Form 4 Sol-Gel Technologies For: Mar 24 Filed by: Opaleye Management Inc.

Tue, 24 Mar 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260324/26210386.html

Form 4 Sol-Gel Technologies For: Mar 24 Filed by: Opaleye Management Inc.

Tue, 24 Mar 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260324/26210386.html

Form EFFECT Sol-Gel Technologies

Tue, 24 Mar 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260324/26205913.html

Form EFFECT Sol-Gel Technologies

Tue, 24 Mar 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260324/26205913.html

Sol-Gel Technologies prices $33.1 million share offering at $72 each

Tue, 24 Mar 2026 04:19:46 -0400

Sol-Gel Technologies Ltd. (NASDAQ: SLGL) announced the pricing of an underwritten public offering of 459,112 ordinary shares at $72.00 per share, generating gross proceeds of approximately $33.1 million before fees and expenses.

The Israeli dermatology company said the offering was oversubscribed and included participation from new and existing investors, including Great Point Partners, Trails Edge Capital Partners, Surveyor Capital, Affinity Asset Advisors, Squadron Capital Management, Stonepine Capital Management and AuGC BioFund.

The offering is expected to close on or about March 25, 2026, subject to customary closing conditions. TD Cowen and LifeSci Capital are serving as joint book-running managers for the transaction.

Sol-Gel